Wednesday, July 8, 2026

biotech · Choroideremia · X-Linked Retinitis Pigmentosa · FDMT

4D Molecular Therapeutics

4D Molecular Therapeutics is a biotech organization headquartered in Emeryville, USA. It trades on NYSE under ticker FDMT. Primary therapeutic focus areas include Choroideremia, X-Linked Retinitis Pigmentosa, Macular neo

5858 Horton St, 455, Emeryville, California 94608, US HQ
2013 Founded
213 Employees
Public company Type
FDMT · NYSE Ticker
Company details
Status
Public
HQ
5858 Horton St, 455, Emeryville, California 94608, US
Founded
2013
Employees
213
Programs
19
Drugs
13
Patents
15
Clinical program

MRx0518 Capsules

Phase 1 · small molecule · Melanoma

MRx0518 Capsules for Melanoma is a Phase 1 program (small_molecule) at 4D Molecular Therapeutics with 1 ClinicalTrials.gov record(s).

← All 4D Molecular Therapeutics projects Phase 1 small molecule active

Internal code C/35/2017

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
4D Molecular Therapeutics
Phase
Phase 1
Modality
small_molecule
Indication
Melanoma
Status
active
Trials
1